Handelsbanken Fonder’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,000
| Closed | -$646K | – | 1582 |
|
|
2023
Q4 | $646K | Sell |
11,000
-900
| -8% | -$50.6K | ﹤0.01% | 1008 |
|
|
2023
Q3 | $518K | Sell |
11,900
-65,000
| -85% | -$2.32M | ﹤0.01% | 1036 |
|
|
2023
Q2 | $2.78M | Buy |
76,900
+1,300
| +2% | +$53.6K | 0.01% | 499 |
|
|
2023
Q1 | $2.81M | Hold |
75,600
| – | – | 0.02% | 484 |
|
|
2022
Q4 | $3.42M | Sell |
75,600
-100
| -0.1% | -$6.47K | 0.02% | 458 |
|
|
2022
Q3 | $5.29M | Sell |
75,700
-6,500
| -8% | -$481K | 0.04% | 398 |
|
|
2022
Q2 | $5.52M | Buy |
82,200
+30,000
| +57% | +$1.91M | 0.04% | 413 |
|
|
2022
Q1 | $4.29M | Hold |
52,200
| – | – | 0.02% | 471 |
|
|
2021
Q4 | $7.66M | Hold |
52,200
| – | – | 0.04% | 402 |
|
|
2021
Q3 | $9.23M | Buy |
52,200
+10,000
| +24% | +$1.61M | 0.05% | 348 |
|
|
2021
Q2 | $6.82M | Sell |
42,200
-34,700
| -45% | -$5.57M | 0.04% | 425 |
|
|
2021
Q1 | $13.2M | Sell |
76,900
-5,000
| -6% | -$990K | 0.07% | 252 |
|
|
2020
Q4 | $18M | Buy |
81,900
+800
| +1% | +$173K | 0.11% | 192 |
|
|
2020
Q3 | $13.5M | Buy |
81,100
+32,400
| +67% | +$4.43M | 0.1% | 204 |
|
|
2020
Q2 | $5.56M | Buy |
48,700
+11,200
| +30% | +$1.09M | 0.05% | 320 |
|
|
2020
Q1 | $2.88M | Buy |
37,500
+6,000
| +19% | +$538K | 0.06% | 154 |
|
|
2019
Q4 | $4.06M | Sell |
31,500
-25,000
| -44% | -$2.41M | 0.07% | 158 |
|
|
2019
Q3 | $4.4M | Buy |
56,500
+15,500
| +38% | +$1.45M | 0.09% | 149 |
|
|
2019
Q2 | $4.22M | Buy |
41,000
+1,000
| +3% | +$77.9K | 0.08% | 163 |
|
|
2019
Q1 | $2.93M | Buy |
+40,000
| New | +$2.72M | 0.06% | 162 |
|
Other funds holding MRTX
Handelsbanken Fonder's MRTX Position: Q1 2024 in Review
Handelsbanken Fonder sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 11,000 shares — an estimated $646K sold.
Handelsbanken Fonder first reported a position in MRTX in Q1 2019 and held it in 20 quarters. The position peaked at $18M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Handelsbanken Fonder reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Handelsbanken Fonder sold 11,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $646K.
- Handelsbanken Fonder first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- Handelsbanken Fonder's Mirati Therapeutics, Inc. Common Stock position peaked at $18M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Handelsbanken Fonder's 13F filing for Q1 2024, filed 13 May 2024.